[Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].
OBJECTIVE
To evaluate the efficacy and toxicity of campto (CPT-11) monotherapy or combined with 5Fu + leucovorin (CF) in advanced large intestinal cancer.


METHODS
186 such patients were divided into campto monotherapy group and CPT-11 plus 5Fu + CF [De Gramont (DGM) or Mayo protocal] groups. The mean dose of CPT-11 was 270 mg/m(2) alone in the monotherapy group and 150 mg/m(2) in the combination group. Campto was given as iv infusion in no less than 30-minutes.


RESULTS
186 patients were eligible for response evaluation. The response rates were 27.9% in the monotherapy group, 32.7% in CPT-11 + DGM and 27.3% in CPT-11 + Mayo group. For 55 untreated patients, the response rates of monotherapy, Campto + DGM and Campto + Mayo regime groups were 33.3%, 28.9% and 50.0%. For 131 treated patients, they were 26.4%, 34.8% and 22.2%, respectively. The toxicities of the whole group were 16.0% cholinergic syndrome, 51.9% delayed diarrhea and 19.8% leucopenia. There were 2 treatment-related deaths.


CONCLUSIONS
The efficacy and toxicities of campto are similar as compared with the reports by other investigators.
Zhang
Li
L
Cancer Center of Sun Yat-sen University, Guangzhou 510060, China.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged
D000077146:Irinotecan; D002166:Camptothecin